The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Biomarkers in Parkinson’s disease (recent update)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.10.018 · Cited by 7,429
Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., Vankova, J., Black, J., Harsh, J., Bassetti, C., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1553 · Cited by 1,126
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 3×
“Furthermore, Cheng et al. (2010) proposed that degeneration of axons, not cell bodies, is the primary determinant of clinically apparent progression of disease, and that future experimental therapeutics intended to halt disease progression will benefit from the distinct mechanisms of axonal degeneration. Shtilbans and…”
InfluentialFrom prediction error to incentive salience: mesolimbic computation of reward motivation.
Berridge, K. C. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.07990.x · Cited by 700
Addiction circuitry in the human brain
Volkow, N. D., Wang, G.-J., Fowler, J. S., & Tomasi, D. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134625 · Cited by 592
MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders
Geuze, E., Vermetten, E., & Bremner, J. D. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001579 · Cited by 412
del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343
Oxidized proteins: Mechanisms of removal and consequences of accumulation
Dunlop, R. A., Brunk, U. T., & Rodgers, K. J. (2009) · IUBMB Life · doi:10.1002/iub.189 · Cited by 124
Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
Fonteh, A. N., Harrington, R. J., Huhmer, A. F., Biringer, R. G., Riggins, J. N., & Harrington, M. G. (2006) · Disease Markers · doi:10.1155/2006/202938 · Cited by 113
Impulse control disorders in Parkinson's disease
Vilas, D., Pont-Sunyer, C., & Tolosa, E. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70026-8 · Cited by 77
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Early Detection of Parkinson’s Disease Using Deep Learning and Machine Learning
Wang, W., Lee, J., Harrou, F., & Sun, Y. (2020) · IEEE Access · doi:10.1109/access.2020.3016062 · Cited by 397
Biomarkers of Parkinson’s disease: Present and future
Miller, D. B., & O’Callaghan, J. P. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 358
Biomarkers for Parkinson’s Disease: Recent Advancement
Lotankar, S., Prabhavalkar, K. S., & Bhatt, L. K. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0183-5 · Cited by 282
Prashanth, R., Dutta Roy, S., Mandal, P. K., & Ghosh, S. (2016) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2016.03.001 · Cited by 244
New hope for Parkinson’s disease treatment: Targeting gut microbiota
Fan, H., Sheng, S., & Zhang, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13916 · Cited by 66
Iron Redox Chemistry and Implications in the Parkinson’s Disease Brain
Abeyawardhane, D. L., & Lucas, H. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4609702 · Cited by 35
Fifel, K., Piggins, H., & Deboer, T. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.02.005 · Cited by 30
Metadata
- Authors
- Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y., & Ebadi, M.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 63
- Issue
- 3
- Pages
- 201-229
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W1967089050
- Cited by
- 242
- References
- 11
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.